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Background. Pertussis is estimated to cause 2 percent of childhood deaths globally and is a growing public health problem in 
developed countries despite high vaccination coverage. Infants are at greatest risk of morbidity and mortality. Maternal vaccination 
during pregnancy may be effective to prevent pertussis in young infants, but population-based estimates of disease burden in infants 
are lacking, particularly in low-income countries. The objective of this study was to estimate the incidence of pertussis in infants less 
than 6 months of age in Sarlahi District, Nepal.
Methods. Nested within a population-based randomized controlled trial of influenza vaccination during pregnancy, infants 
were visited weekly from birth through 6 months to assess respiratory illness in the prior week. If any respiratory symptoms had 
occurred, a nasal swab was collected and tested with a multitarget pertussis polymerase chain reaction (PCR) assay. The prospective 
cohort study includes infants observed between May 2011 and August 2014.
Results. The incidence of PCR-confirmed Bordetella pertussis was 13.3 cases per 1000 infant-years (95% confidence interval, 
7.7–21.3) in a cohort of 3483 infants with at least 1 day of follow-up.
Conclusions. In a population-based active home surveillance for respiratory illness, a low risk for pertussis was estimated 
among infants in rural Nepal. Nepal’s immunization program, which includes a childhood whole cell pertussis vaccine, may be 
effective in controlling pertussis in infants.
Keywords. epidemiology; incidence; infants; Nepal; pertussis.
 
A resurgence of pertussis across age groups has occurred in 
several countries in recent years [1]. Middle- and high-income 
countries that use an acellular pertussis vaccine for the primary 
vaccination series have been particularly affected [2, 3], and 
infants and adolescents have experienced the greatest increase 
[4]. Factors that may contribute to the increased risk of pertus-
sis include rapidly waning immunity from those vaccinated with 
acellular vaccines [1, 5, 6], asymptomatic transmission from indi-
viduals vaccinated with acellular vaccines [7], genetic adaption of 
Bordetella pertussis [8], vaccination delay or refusal [9], improved 
surveillance and laboratory capabilities [2], and overall increased 
awareness of the continuing circulation of B pertussis [1].
Some countries experiencing epidemic pertussis, including 
the United States, United Kingdom, and Argentina, now rec-
ommend pertussis immunization in pregnancy and vaccination 
of close contacts [10, 11] to protect the youngest infants from 
pertussis before they can be vaccinated themselves [12]. Recent 
data from maternal vaccination trials demonstrate the ability of 
antibodies to be transferred from mothers to their infants in 
pregnancy and their persistence in infants [13].
Global estimates of pertussis show the highest childhood 
burden in Southeast Asia [14]. In this region, maternal pertussis 
vaccination during pregnancy may be a way to protect infants, 
similar to the approach using tetanus toxoid vaccine. However, 
globally only 1 population-based estimate of pertussis in infants 
from birth has been conducted (Senegal) [15], and surveillance 
and laboratory capabilities in Asia are lacking [16, 17]. The 
World Health Organization (WHO) recently recommended 
that countries using whole cell pertussis vaccines continue to do 
so in light of recent data indicating that acellular pertussis vac-
cines are less effective than whole cell pertussis vaccines [18]. 
Population-based data are needed, especially in low-income 
settings, to provide a more accurate estimate of the burden of 
pertussis in infants to inform childhood and maternal immuni-
zation policies [19, 20].
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We report on a prospective cohort study following infants 
weekly in their homes to monitor for pertussis disease from 
birth to age 6  months. The objective was to provide a pop-
ulation-based estimate of laboratory-confirmed pertussis 




The study was nested within 2 consecutive randomized con-
trolled trials of maternal influenza vaccination during preg-
nancy set in the Sarlahi District, located in the central Terai 
(low-lying plains) region of Nepal [21]. At the start of the trial, 
prevalent pregnancies were identified through a census of all 
households in the catchment area. For the duration of the trial, 
field workers visited all households in the communities, every 
5 weeks, where married women (15–40 years) resided, for sur-
veillance of incident pregnancies. Once a pregnancy was iden-
tified, women provided consent and were enrolled. From April 
25, 2011 through September 9, 2013, women between 17 and 34 
weeks gestation were randomized and vaccinated with either an 
influenza vaccine or placebo. The study was a population-based 
prospective cohort of infants followed from birth through 
6 months postpartum. Approval for the study was obtained from 
the Institutional Review Boards at the Johns Hopkins Bloomberg 
School of Public Health, Cincinnati Children’s Medical Center, 
the Institute of Medicine at Tribhuvan University, Kathmandu, 
and the Nepal Health Research Council. The trials are registered 
at Clinicaltrials.gov (NCT01034254).
Data Collection
At baseline, information was collected on household structure, 
socioeconomic status, and demographics. At enrollment, date 
of last menstrual period and pregnancy history data were col-
lected. As soon as possible after delivery, the mother and infant 
were visited to collect detailed birth information including 
infant weight and breastfeeding status. From birth through 
6  months, postpartum infants were visited weekly by a field 
worker, who recorded any infant respiratory symptoms in the 
past 7  days. If an infant had any of the following symptoms, 
a mid-nasal nylon flocked swab was collected: fever, cough, 
wheeze, difficulty breathing, or ear infection. Starting on August 
17, 2012, new symptoms, more specific for pertussis, were 
added to the weekly morbidity visit: apnea, cyanosis, cough 
with vomit, or whoop/whooping cough. The swabs were stored 
for up to 1 week at room temperature in PrimeStore Molecular 
Transport Medium (Longhorn Diagnostics LLC, Bethesda, 
MD). In addition to these signs, mothers were asked which, if 
any, infant vaccinations were received in the past 7 days, includ-
ing pertussis vaccination [22]. Mid-nasal swabs were also col-
lected on a weekly basis from mothers from enrollment through 
6 months postpartum who reported fever plus one additional 
morbidity (cough, sore throat, nasal congestion, or myalgia). 
All nasal swabs collected from infants were tested for B pertus-
sis, Bordetella parapertussis, and Bordetella bronchispetica. Only 
the nasal swabs of mothers whose infants tested positive for any 
of these pathogens were tested for the same pathogens.
Laboratory Assays
Real-time polymerase chain reaction (PCR) testing was con-
ducted at the University of Washington’s Molecular Virology 
Laboratory according to previously published methods [23]. 
Two-target PCR was used to assess the presence of 3 Bordetella 
species: B pertussis, B parapertussis, and B bronchiseptica. 
The amplified targets were chromosomal repeated insertion 
sequence IS481 (IS) and the polymorphic pertussis toxin ptxA 
promoter region (PT).
After amplification, the melting points of the amplicons were 
measured in an iCycler (Bio-Rad). A sample was interpreted as 
positive when the target(s) had a melting temperature within 
the species-specific acceptable range and a computed tomogra-
phy ≤42. A sample was negative if none of the targets tested pos-
itive or a single positive target was not reproducible. Maternal 
nasal swabs were tested for those mothers whose infants tested 
positive for any Bordetella species
Polymerase chain reaction was also performed for several 
viral infections (influenza, rhinovirus [RV], respiratory syncy-
tial virus [RSV], bocavirus [BoV], human metapneumovirus, 
coronavirus, adenovirus, and parainfluenza [1–4]) as previously 
described [21].
Analytic Dataset
Of 3693 women enrolled, 3646 infants were live born to 3621 
women (Supplementary Figure 1). Infants were included in this 
analysis if they were followed for any length of the follow-up 
period (0 to 180  days); median total follow-up was 146  days 
per infant (Supplementary Figure 2). The final dataset consists 
of 3483 infants, contributing 1280 infant-years of observation, 
with at least 1 follow-up visit during the first 6  months. This 
includes infants from the entire trial period, both before and 
after more pertussis-specific additions to the weekly symptom 
questionnaire.
At baseline, data on household structure were gathered. At 
enrollment, women reported their literacy status (binary) and 
pregnancy history. The field workers identified their ethnicity 
into 2 broad groups (Pahadi, a group originating from the hills; 
or Madeshi, a group originating from north India) from names 
and observation. Women were categorized as nulliparous or 
multiparous. Responses to 25 questions about household con-
struction, water and sanitation, and household assets were used 
to develop an index to measure the socioeconomic status of 
households. Binary variables for each of the 25 questions and a 
mean SES score were calculated for each household.
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Gestational age was measured using a woman’s report of date 
of last menstrual period during pregnancy surveillance. Birth 
weight was collected as soon as possible after birth using a digi-
tal scale (Tanita model BD-585, precision to nearest 10 grams). 
Birth weights collected >72  hours after birth were excluded 
from the analysis. Small for gestational age (SGA) was calcu-
lated using the sex-specific 10th percentile cutoff described by 
Alexander et  al [24] and the INTERGROWTH-21 standards 
[25]. Women were asked within how many hours of birth 
breastfeeding was initiated and binary breastfeeding categories 
were created (≤1 hour versus >1 hour postdelivery).
Statistical Analysis
Incidence was calculated as the number of pertussis cases per 
1000 infant-years at risk. Poisson exact 95% confidence inter-
vals (CIs) were constructed. Characteristics of infant pertussis 
cases were compared with nonpertussis cases using bivariate 
Poisson regression. Characteristics of all pertussis respiratory 
episodes were compared with nonpertussis respiratory epi-
sodes; t tests were used for continuous predictors and Fisher’s 
exact tests were used for categorical associations due to the low 
number of pertussis episodes. All statistical analyses were con-
ducted in Stata/SE 14.1.
RESULTS
A total of 3483 infants had 4283 episodes of respiratory illness 
between May 18, 2011 and April 30, 2014. Thirty-nine percent 
(n = 1350) of infants experienced no respiratory episodes. The 
incidence of respiratory illness was 3.6 episodes per infant-year 
(95% CI, 3.5–3.7). Mean episode duration was 4.7  days (95% 
CI, 4.6–4.9). A  total of 3930 (92%) episodes were matched 
to 1 or more pertussis-tested nasal swabs from 2026 infants 
(Supplementary Figure 1).
Seventeen cases of B pertussis were identified from 19 nasal 
swabs (nasal swabs were positive on 2 consecutive weeks for 2 
infants). The incidence of PCR-confirmed B pertussis was 13.3 
cases per 1000-infant years (95% CI, 7.7–21.3). Five cases of B 
parapertussis were detected with an incidence of 3.9 cases per 
1000 infant-years (95% CI, 1.3–9.1). No cases of B bronchisep-
tica were identified.
Bordetella Pertussis
The average pertussis episode duration was 8  days (range, 
2–33) (Table 1). Mean age of onset of symptoms was 83 days 
(range, 19–137) (median, 80; interquartile range, 63–109). The 
most common symptoms were cough, difficulty breathing, and 
cough with vomit. None of the additional symptoms related 
to pertussis that were added in year 2 (cyanosis, apnea, cough 
with vomit, and whoop) resulted in collection of nasal swabs 
based solely on these additional symptoms. Pertussis episodes 
were statistically significantly more likely to include difficulty 
breathing, cough with vomit, and whoop compared with other 
respiratory illness. Six infants had at least 1 pertussis vaccina-
tion before pertussis disease onset (three <2 weeks and three 
>2 weeks before pertussis illness) with a mean of 18 days from 
vaccination to illness compared with 49 days for nonpertussis 
episodes (P = .03). Five infants received their first pertussis vac-
cination postpertussis disease onset, whereas 6 infants received 
no pertussis vaccination in the first 180 days. Three fourths of 
pertussis episodes were coinfected with at least 1 virus, with RV 
and BoV the most common. Cases of pertussis were more likely 
to be infected with BoV than respiratory cases due to causes 
other than pertussis. The majority of cases occurred between 
February 2013 and January 2014 (Figure 1).
No statistically significant differences between risk fac-
tors for pertussis and nonpertussis cases (Table 2) were docu-
mented. Given the low number of pertussis cases, the lack of 
a statistical association is not evidence of nonassociation. No 
deaths occurred in infants who had pertussis. Of the 8 mothers 
of B pertussis-positive infants who had a nasal swab collected 
(14 nasal swabs total) during their own follow-up, none were 
positive for any pertussis species.
Bordetella Parapertussis
The 5 B parapertussis cases were primarily male whose mothers 
were primiparous, literate, and Pahadi ethnicity (Supplementary 
Table 1). No mothers of infants who had B parapertussis had a 
nasal swab collected during follow-up.
The average B parapertussis episode duration was 4  days 
(Supplementary Table 2). Mean age of onset of symptoms was 
58 days with a range of 7–95 days. The most common symp-
toms were cough and wheeze. Rhinovirus and RSV were the 
only coinfections observed. All B parapertussis cases occurred 
between September 2011 and February 2012 (Figure 1).
DISCUSSION
A low incidence of pertussis and generally mild clinical pre-
sentation were found in infants <6  months in Nepal. To our 
knowledge, this represents one of the first population-based 
active surveillance of PCR-confirmed pertussis among young 
infants in Asia. Acellular pertussis vaccine trials conducted in 
the 1990s found the average pertussis incidence in the whole 
cell vaccine groups ranged from 1 to 37 cases per 1000 infant-
years [26]. Our finding of 13 B pertussis cases per 1000 infant-
years was on the lower end of this range. In the United States 
in 2014, the estimated pertussis incidence in infants less than 
6 months was 2 cases per 1000 infant-years [27], much lower 
than observed in our study; however, this passive surveil-
lance system likely vastly underestimates pertussis incidence. 
Thus, there is a need for active surveillance data such as ours. 
Furthermore, given our highly sensitive case detection method, 
many of our pertussis cases would likely not have been detected 
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in the previous acellular pertussis vaccine trials. More stringent 
respiratory symptom criteria would have lowered our incidence 
estimate even further. The low incidence was found in a popula-
tion where pentavalent vaccine (Pentavac: Diphtheria, Tetanus, 
Pertussis [Whole Cell], Hepatitis-B and Haemophilus Type b 
Conjugate Vaccine; Serum Institute of India Pvt. Ltd), sched-
uled for administration at 6, 10, and 14 weeks, is received with 
significant delays (7% of infants received all 3 recommended 
pertussis vaccines by 6  months) [22]. These data support the 
WHO’s recommendation that countries using whole cell per-
tussis vaccine continue to do so given that the majority of out-
breaks have been concentrated in countries using the acellular 
pertussis vaccine [2]. Recent studies suggest that protection 
from acellular pertussis vaccine is not as strong or long lasting 
as that conferred by the whole cell pertussis vaccine [6, 28].
Another contributing factor to the low pertussis incidence 
observed could be that surveillance was conducted during a 
period of low pertussis transmission. Pertussis is a cyclical dis-
ease, thought to peak every 2 to 4 years, and we may have cap-
tured the burden at a low circulation period [6]. We observed over 
70% of our B pertussis cases over a 1-year period. This increase 
from earlier observation periods could indicate a temporary rise 
in pertussis consistent with its cyclical pattern or a true increase 
in the baseline burden. Previous research on pertussis seasonal-
ity has in different places and time periods demonstrated various 
periods of peak transmission or no discernable patterns [29, 30]. 
Although our data do not support a seasonal pattern, the num-
bers observed are too low to be conclusive.
Pertussis symptom duration and severity were mild com-
pared with the classic pertussis case presentation. Only 3 of 
the 17 cases fulfilled the WHO criteria, which requires a mini-
mum of 2 weeks of cough, whoop, or posttussive vomiting [31]. 
Studies on pertussis in infants have generally been clinic-based, 
hospital-based, or in an outbreak, which therefore required a 
certain severity of illness for parents to recognize a need for 
medical attention [29, 30, 32]. These study designs and passive 
surveillance efforts therefore may have missed milder pertussis 
cases [33]. Our study, which required only 1 respiratory symp-
tom for a nasal swab to be collected, had increased sensitivity 
to detect a range of pertussis case presentations. An alterna-
tive explanation for the mild cases seen could be an increase 
in the proportion of mild compared with severe pertussis cases 
in Nepal.
Although cough, difficulty breathing, and cough with 
vomit were the most common symptoms, no symptom was 
present in all B pertussis cases. During an epidemic period in 
Washington state, among infants <1 year, who had a minimum 
of 14 days cough plus an additional symptom, 82% had post-
tussive emesis, 29% had apnea, 26% had whoop, and 42% had 
cyanosis [32]. A study of US neonates with pertussis showed 
the symptom prevalence to be 97% for cough, 91% for cya-
nosis, 58% for apnea, and 3% for fever [34]. Our study found 
lower or equal symptom prevalence with the exception of 
fever. Fever prevalence was higher in our study, similar to that 
found in Peru [29].
Although not statistically significant, infants with pertussis 
were more likely to have been born preterm, low birth weight, Figure 1. Timing of respiratory episodes.






P ValueaCharacteristic Proportion Mean Proportion Mean
Symptomsb
Cough 62% 71% .62
Difficulty breathing 40% 65% .05
Cough with vomit 12% 50% .00
Wheeze 45% 47% .99
Fever 53% 47% .64
Whoop 6% 33% .01
Apnea 4% 17% .08
Cyanosis 1% 8% .09
Ear Infection 5% 6% .59
Episode duration (days) 5 8 .07
Age at episode start (days) 91 83 .54
Coinfections
RV 50% 53% .99
BoV 5% 24% .01
PIV3 4% 12% .17
RSV 9% 6% .99
Influenza 5% 6% .55
MPV 5% 6% .57
CoV 8% 6% .99
PIV1 2% 0% .99
PIV2 1% 0% .99
PIV4 2% 0% .99
AdV 2% 0% .99
Vaccination
Received 1st pertussis vaccination 38% 35% 0.99
Days since vaccination 49 18 0.03
Abbreviations: AdV, adenovirus; BoV, bocavirus; CoV, coronavirus; MPV, human metapneumovirus; PIV, parain-
fluenza; RSV, respiratory syncytial virus; RV, rhinovirus. 
at tests were used for continuous predictors and Fisher’s exact tests were used for categorical predictors; 
statistical significance of P < .05 indicated in bold.
bCough with vomit, apnea, whoop, and cyanosis were only captured in year 2; denominator for these symp-
toms was 2034 episodes.
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and SGA, and their mothers were more likely to be primipa-
rous. These findings are similar to previous studies showing no 
difference in pertussis cases by sex [29, 35, 36] or crowding [35] 
but showing differences by birth weight [36]. Coinfections were 
common, consistent with findings from other hospital-based 
studies [33]. Codetection of B pertussis and B parapertussis 
with respiratory viruses may be due to asymptomatic pertussis 
carriage.
The incidence of B parapertussis of 4 cases per 1000 per-
son-years was comparable to that of 2 per 1000 person-years 
found in the Italian acellular pertussis vaccine trial in 1992–
1993 [37]. The duration of illness was shorter for B parapertussis 
with a maximum duration of 6 days compared with a maximum 
of 33 days for B pertussis. A milder presentation is consistent 
with clinical knowledge of B parapertussis infection [37, 38]. 
Bordetella parapertussis cases occurred only during a 5-month 
period.
Limitations
There were several study design limitations. We cannot be cer-
tain whether the reported symptoms were caused by pertussis, 
another organism, or whether symptoms were related to 2 or 
more etiologic agents. We were unable to perform multivariate 
regression modeling for characteristics associated with pertus-
sis disease and pertussis cases due to the small number of cases 
we detected.
Infant respiratory symptoms were reported by parents, who 
may have missed signs that might have been observed by a 
healthcare worker. However, the criteria for collection of the 
nasal swab were broad and did not require sophisticated clinical 
skills. However, apnea and cyanosis may have been difficult for 
parents to identify. Although the criteria for specimen collection 
changed in year 2, no infant experienced a pertussis-specific 
symptom in isolation without also having one of the origi-
nally specified respiratory symptoms. These data support our 
assumption that we were unlikely to have missed pertussis cases 
in year 1 with our less sensitive respiratory symptom criteria.
Nasal swabs were collected in the mid-nasal region for 
influenza virus detection, which may have lowered the sensi-
tivity of pertussis detection. In a field site, the acceptability of 
an additional nasopharyngeal swab would likely have increased 
the participant refusal rate. This would have decreased the gen-
eralizability of our results to the entire population. Although 
nasopharyngeal swabs or nasopharyngeal aspirates are the rec-
ommended specimen collection method [39], the nasopharyn-
geal region was established as the collection area of choice when 
the diagnostic measure was culture, which has low sensitivity. 
Recent data demonstrated the comparability of using mid-nasal 
versus nasopharyngeal swabs in PCR pertussis detection [40].
Strengths
Strengths of the study included being a population-based, pro-
spective study, with very low refusal rates. Risk factors, clini-
cal symptoms, and coinfections were prospectively identified 
without the potential bias that may occur when these data 
are collected retrospectively or in clinical settings. The com-
munity-based design allows generalizability of these results 
to the entire population and not just those seeking care at a 
health facility or in an outbreak situation. The Sarlahi District 
is located in the Terai region where the majority of Nepalese 
reside, and it has similar demographics to the entire population 
of Nepal [41]. Sarlahi’s location near sea level and on the border 
with India supports the generalizability of these results to many 
populations living on the Indian subcontinent. The weekly 
active surveillance with sensitive criteria for pertussis testing 
was able to detect mild and atypical pertussis cases, which may 
Table 2. Poisson Regression for Risk Factors for Pertussis in Infants
Risk Factor
Nonpertussis Infants Pertussis Infants Unadjusted
(n = 3466) (n = 17) IRR 95% CI P Value
Male Sex 53% 59% 1.3 0.5 − 3.4 .61
Preterm (<37 weeks) 12% 24% 2.2 0.7 − 6.6 .18
Low birth weight (<2500 grams) 25% 36% 1.7 0.5 − 5.9 .38
Small for gestational age (IG) 37% 50% 1.7 0.5 − 5.8 .41
Small for gestational age (A) 48% 55% 1.3 0.4 − 4.3 .65
Breastfed in 1st hour 35% 38% 1.1 0.4 − 3.0 .86
Primiparous 42% 59% 2.0 0.8 − 5.2 .16
Pahadi ethnicity 58% 69% 1.6 0.6 − 4.6 .37
Literate 61% 60% 1.6 0.6 − 4.6 .37
Household size (mean) 5 4 0.9 0.7 − 1.1 .39
SES score (mean) 0.39 0.35 0.2 0.0 − 8.6 .42
Age (days) at first pertussis vaccination (mean) 85 96 1.0 1.0 − 1.0 .17
1st pertussis vaccination received by 6 months 56% 65% 1.5 0.5 − 3.9 .47
Abbreviations: A, Alexander standards; CI, confidence interval; IG, INTERGROWTH-21st standards; IRR, incidence rate ratios; SES, socioeconomic status. 
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have been missed by previous traditional surveillance. The 
multitarget PCR method allowed highly sensitive and specific 
detection of 2 additional Bordetella species beyond the primary 
B pertussis target.
CONCLUSIONS
We observed a low incidence of pertussis in infants in a whole 
cell vaccine environment. Pertussis cases were generally milder 
than expected compared with traditional pertussis clinical defi-
nitions. These data support clinicians considering pertussis 
in their differential diagnosis of infants with mild respiratory 
symptoms. Policymakers in Nepal will need to weigh the benefit 
of an additional prenatal pertussis vaccine or a switch to acellu-
lar primary pertussis vaccine with the low burden of pertussis 
in infants less than 6 months.
Our study demonstrated that mid-nasal swabs were able 
to detect pertussis using a sensitive multitarget PCR. The less 
invasive mid-nasal nasal swab is an attractive alternative for 
pertussis nasal swab collection, and further research is needed 
to compare this collection site with nasopharyngeal swabs. In 
the future, this method may enhance population-based surveil-
lance efforts.
Supplementary Data
Supplementary materials are available at Journal of the Pediatric Infectious 
Diseases Society online.
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